4 hours ago
1
MarketBeat
Tue, April 14, 2026 astatine 9:50 AM CDT 9 min read
-
Johnson & Johnson reported a first‑quarter bushed with worldwide income up 6.4% operationally and raised full‑year operational income guidance to 5.9%–6.9%, contempt an approximate 540‑basis‑point headwind from Stelara biosimilar competition.
-
Momentum was driven by Innovative Medicine — oncology led the complaint with DARZALEX astatine $4 cardinal and beardown double‑digit maturation for CARVYKTI, TECVAYLI and TALVEY — portion immunology launches (including the caller oral IL‑23 “ikotide”) and Tremfya (up ~64%) added further upside.
-
Profitability was pressured by early‑year motorboat investments, tariffs and prior‑year talc-related accounting swings, yet absorption nudged up adjusted EPS guidance, announced a 3.1% dividend increase (64th consecutive year) and reaffirmed plans to put $55 cardinal successful U.S. manufacturing and R&D done aboriginal 2029.
-
Interested successful Johnson & Johnson? Here are 5 stocks we similar better.
-
A Q2 2026 Playbook for Navigating Market Uncertainty
Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 results that executives said enactment the institution “off to a accelerated start” successful what absorption has described arsenic a twelvemonth of accelerated growth. On the net call, Chairman and CEO Joaquin Duato pointed to a “beat connected statement and raised guidance,” driven by operational income maturation of 6.4% and momentum crossed some Innovative Medicine and MedTech.
Vice President of Investor Relations Darren Snellgrove said worldwide income were $24.1 billion, up 6.4% operationally, contempt an “approximate 540 ground constituent headwind” from Stelara. U.S. maturation was 8.3% and maturation extracurricular the U.S. was 3.9%.
→ 3 Surprising S&P 500 Outperformers of 2026
-
Quiet Outperformance From an Overlooked Dividend ETF
Snellgrove added that acquisitions and divestitures provided a nett affirmative 110 basis-point interaction to worldwide growth, “primarily driven by the Intra-Cellular acquisition.”
Innovative Medicine income were $15.4 billion, up 7.4% operationally, contempt an “approximate 920 ground constituent headwind from Stelara,” Snellgrove said. Growth was 9.6% successful the U.S. and 4.3% extracurricular the U.S., with a nett affirmative 180 basis-point publication from acquisitions and divestitures, again “primarily owed to the Intra-Cellular acquisition.”
→ Microsoft’s Copilot Problem Isn’t What You Think
-
Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector
Duato highlighted aggregate myeloma arsenic a cardinal driver, calling DARZALEX the company’s “number 1 product,” with income of $4 cardinal and operational maturation of 18%. Snellgrove said DARZALEX maturation of 17.8% was driven by stock gains “across each lines of therapy,” including astir 12 points successful the frontline setting. He besides cited continued maturation successful newer myeloma assets, including CARVYKTI (approximately $600 cardinal successful sales, up 57.4%), TECVAYLI (up 30.1% with sequential maturation of 14.2%), and TALVEY (up 72.8%).
English (CA) · 
English (US) · 
Spanish (MX) ·